Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use

{
  "publication_number": "US6531491B1",
  "country": "US",
  "kind": "B1",
  "title": "Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use",
  "abstract": "Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.",
  "claims": [
    "1. A compound of the Formula I: wherein: R 1 is an unsubstituted aryl or substituted or unsubstituted heteroaryl, or a group of the formula CH═CH - R 3 or CH═N - R 3 where R 3 is a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; and R 2 is Y - X, where Y is NH, and X is substituted or unsubstituted Ar, heteroaryl, NH-(alkyl), NH-(cycloalkyl), NH-(heterocycloalkyl), NH(aryl), NH(heteroaryl), NH-(alkoxyl), or NH-(dialkylamide), where Ar is aryl; or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.",
    "2. A compound of the Formula III: wherein: R 1 is a substituted or unsubstituted aryl or heteroaryl, or a group of the formula CH═CH - R 3 or CH═N - R 3, where R 3 is a substituted or unsubstituted alkyl, cycloalkyl, heterocycloallyl, aryl, or heteroaryl; Y is O, S, C═CH 2, C═O, S═O, SO 2, CH 2, CH═CH 3, NH, or N - (C 1 -C 8 alkyl); R 8 is a substituted or unsubstituted alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxyl, or aryloxyl; and R 10 is independently selected from hydrogen, halogen, and lower-alkyl; or a pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt thereof.",
    "3. A compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt according to claim 2, wherein: R 1 is a substituted or unsubstituted bicyclic heteroaryl, or a group of the formula CH═CH - R 3, where R 3 is a substituted or unsubstituted aryl or heteroaryl; Y is O, S, C═CH 2, C═O, NH, or N - (C 1 -C 8 alkyl); R 8 is a substituted or unsubstituted aryl or heteroaryl, alkyl, and alkenyl; and R 10 is hydrogen or halogen.",
    "4. A compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt according to claim 3, wherein: R 1 is a group of the formula CH═CH - R 3, where R 3 is an unsubstituted heteroaryl; Y is NH; R 8 is a substituted heteroaryl; and R 10 is hydrogen or halogen.",
    "5. A compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt, having the following structure:",
    "6. A pharmaceutical composition comprising: (a) a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt of claim 2; and (b) a pharmaceutically acceptable carrier, diluent, or vehicle therefor.",
    "7. A method of treating a mammalian disease condition mediated by protein kinase activity, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as claimed in claim 2.",
    "8. A method according to claim 7, wherein the mammalian disease condition is associated with tumor growth, cell proliferation, or angiogenesis.",
    "9. A method of modulating the activity of a protein kinase receptor, comprising contacting the kinase receptor with an effective amount of a compound, pharmaceutically acceptable prodrug, pharmaceutically active metabolite, or pharmaceutically acceptable salt as claimed in claim 2.",
    "10. A method according to claim 9, wherein the protein kinase receptor is a VEGF receptor."
  ],
  "cpc": [
    "C07D 401/12",
    "C07D 209/18",
    "C07D 401/14",
    "C07D 403/12"
  ],
  "assignees": [
    "AGOURON PHARAMACEUTICALS INC"
  ],
  "filing_date": "2001-10-25",
  "publication_date": "2003-03-11",
  "grant_date": "2003-03-11",
  "priority_date": "1999-07-02",
  "application_number": "US-98378601-A",
  "family_id": "26839785",
  "citations": [
    "DE273062C",
    "EP0666270A2",
    "EP0816357A1",
    "US5621082A",
    "US5705499A",
    "US5760028A",
    "US5861414A",
    "US5886195A",
    "WO0018761A1",
    "WO8605779A1",
    "WO9319052A1",
    "WO9614843A2",
    "WO9703069A1",
    "WO9703967A1",
    "WO9716447A1",
    "WO9723783A1",
    "WO9734876A1",
    "WO9748697A1",
    "WO9809961A1",
    "WO9814451A1",
    "WO9921845A2",
    "WO9923076A1",
    "WO9923077A1"
  ]
}